Surrey Heartlands

Joint Formulary & PAD

Relugolix with estradiol and norethisterone acetate - Endometriosis

You are here : Home > Formulary Search > Relugolix with estradiol and norethisterone acetate - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

Not assessed for formulary status. An application to APC is required.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Relugolix with estradiol and norethisterone acetate
Indication :
Endometriosis
Group Name :
Keywords :
Brand Names Include :
Ryeqo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Relugolix with estradiol and norethisterone acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.

Committee Recommendations (1)

02 Oct 24 - Not Set

This drug has not yet been assessed for formulary status for endometriosis and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.